Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

• Status: Withdrawn
• Trial end date: 2010-05-10
• Target enrollment: 0
• Participant gender: All

Summary

To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary Intervention

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Medicines Company
• Treatments: Bivalirudin; Hirudins

Criteria

Inclusion Criteria:

• Clinically Documented History of HIT/HITTS

• Suspicion of HIT/HITTS

Exclusion Criteria:

• Bleeding Diathesis

• Ischemic Stroke

• Chronic Thrombocytopenia

• Hematologic Malignancy

• Contraindication to bivalirudin

• Pregnant or nursing mothers